tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Biotechnology'

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

Written by Ι Stock Market Media — June 6, 2018

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...

Read More →
0

Nuvilex, Inc. Moves Closer to Head to Head with Eli Lilly in Phase III Clinical Trials

Nuvilex, Inc. Moves Closer to Head to Head with Eli Lilly in Phase III Clinical Trials

Written by ι Stock Market Media Group Staff — July 25, 2013

Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly’s (NYSE: LLY) blockbuster cancer drug, Gemzar, and doing so with the knowledge that in two independent mid-phase clinical trials, the company’s treatment involving its proprietary living cell encapsulation technology has outperformed the pharmaceutical giant.  Nuvilex has produced better results when compared to historical data for Gemzar, and now the company is ready to use real time, head to ...

Read More →
0

Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It

Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It

Written by ι Stock Market Media Staff — March 26, 2013

Nuvilex, Inc. (OTCQB: NVLX) is a small biotechnology company out of Silver Spring, Maryland, but its future might be anything but small.  As the company diligently prepares for its Phase III pancreatic cancer trials, the almost $30-million the company has invested in its unique and proprietary living cell encapsulation or “Cell-in-a-Box” technology could be money well spent given the return in annual sales that cancer drugs bring ...

Read More →
0

Nuvilex, Inc. ι Diabetes Studies Could Eliminate Need for Daily Insulin Requirements

Nuvilex, Inc. ι Diabetes Studies Could Eliminate Need for Daily Insulin Requirements

Written by ι Stock Market Media Staff — March 18, 2013

When investors look into biotechnology and pharmaceutical companies as an investment opportunity, three areas of research stand out as the most favorable for future returns.  The big three are cancer, heart disease and diabetes research that can eventually lead to corresponding clinical trials.  Well, Nuvilex, Inc. (OTCQB: NVLX) is currently involved in 2 of the 3 – cancer and diabetes.

While Nuvilex prepares for a large-scale, late-phase clinical ...

Read More →
0

Nuvilex, Inc. Another Biotech Changing the Face of Medical Marijuana

Nuvilex, Inc. Another Biotech Changing the Face of Medical Marijuana

Written by ι Stock Market Media Staff — March 14, 2013

In the U.S., there has always been a raised eyebrow in the room when it comes to using marijuana for medicinal purposes, but it’s slowly eroding with more and more states passing legislation in favor of the use of marijuana for health reasons.

Make no mistake about it, medical marijuana is big business and prescription cannabis is now available in 18 states, the nation’s capital, and eleven more states are considering legalizing ...

Read More →
0

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Written by ι Stock Market Media — March 5, 2013

In late January, those with advanced stage pancreatic cancer received some good news when Celgene, Corp (NASDAQ: CELG) announced the results of its large scale phase III trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), held in San Francisco. 

Pancreatic cancer is difficult to diagnose and treat until it is at an advanced stage.  Survival of patients with advanced, inoperable pancreatic cancer ...

Read More →
0
ContactUs.com